DDInter948 DDInter1875
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Trimetrexate {u} (Compound) resembles {v} (Compound) Trimethoprim
Trimetrexate {u} (Compound) binds {v} (Gene) DHFR
Trimetrexate {u} (Compound) causes {v} (Side Effect) Hyponatraemia
Trimetrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluconazole
Trimetrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Trimetrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tuberculin purified protein derivative
Trimetrexate {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Trimetrexate {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Trimetrexate (Compound) resembles Trimethoprim (Compound)
Trimetrexate (Compound) binds DHFR (Gene)
Trimetrexate (Compound) causes Hyponatraemia (Side Effect)
Trimetrexate may cause a minor interaction that can limit clinical effects when taken with Fluconazole
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Trimetrexate may lead to a major life threatening interaction when taken with Mipomersen
Trimetrexate may lead to a major life threatening interaction when taken with Clozapine